Ticker LaunchUplisting · ANCN
Chemomab Therapeutics Ltd.
Formerly Anchiano Therapeutics Ltd.; BioCancell Ltd.
Chemomab Therapeutics Ltd. (ANCN), already reporting to the SEC, moved up to Nasdaq Capital Market on Feb 13, 2019 with an offering at $11.50 per ADS raising $30.5M. Oppenheimer was lead-left underwriter, joined by Ladenburg Thalmann. Goldfarb Gross Seligman and Mayer Brown advised the company and Zysman, Aharoni, Gayer and Mintz advised the underwriters.
At its 2019 listing, Anchiano Therapeutics (now Chemomab Therapeutics) was a clinical-stage biotechnology company developing inodiftagene vixteplasmid, a targeted gene therapy for early-stage non-muscle invasive bladder cancer.
- Status
- Uplisting
- Ticker
- ANCN
- Exchange
- Nasdaq Capital Market
- Listed
- Feb 13, 2019
- Price
- $11.50 per ADS
- Raised
- $30.5M
- Market cap at IPO price
- $85.3M
- First filed
- Jan 7, 2019
- Underwriters
- Oppenheimer and Ladenburg Thalmann
- Company counsel
- Goldfarb Gross Seligman and Mayer Brown
- Underwriters' counsel
- Zysman, Aharoni, Gayer and Mintz
- Sector
- Biotech & pharma
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
- Analyst notes on the filing
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (F-1) first filed Jan 7, 2019
- Latest amendment Feb 11, 2019
- Final prospectus (424B4) Feb 13, 2019
- All filings on EDGAR CIK 1534248
Other Biotech & pharma uplistings in 2019
- BioCardia, Inc.BCDA · Aug 5, 2019 · $10M
- Artelo Biosciences, Inc.ARTL · Jun 25, 2019 · $8M
- Guardion Health Sciences, Inc.GHSI · Apr 8, 2019 · $5M